Alnylam Pharmaceuticals Analyst Ratings
RBC Raises Price Target on Alnylam Pharmaceuticals to $250 From $235, Keeps Outperform Rating
Alnylam Pharmaceuticals Analyst Ratings
Alnylam Pharmaceuticals Analyst Ratings
RBC Capital Sticks to Their Buy Rating for Alnylam Pharma (ALNY)
Strong Financial Growth and Promising Clinical Trials Bolster Buy Rating for Alnylam Pharmaceuticals
Alnylam Pharmaceuticals Analyst Ratings
Wolfe Upgrades Ionis to Outperform, Cites Upcoming Catalysts
Alnylam Pharmaceuticals Analyst Ratings
Alnylam Pharmaceuticals Analyst Ratings
Alnylam Pharmaceuticals Analyst Ratings
Alnylam Pharmaceuticals Analyst Ratings
Alnylam Pharmaceuticals Analyst Ratings
Maintaining Hold on Alnylam Pharmaceuticals Amid Clinical and Financial Uncertainties
Alnylam Pharmaceuticals Analyst Ratings
Alnylam Pharma (ALNY) Was Downgraded to a Hold Rating at Goldman Sachs
Cantor Fitzgerald Reiterates Neutral on Alnylam Pharmaceuticals, Maintains $165 Price Target
Alnylam Pharmaceuticals Analyst Ratings
Alnylam Pharmaceuticals Analyst Ratings
JP Morgan Maintains Neutral on Alnylam Pharmaceuticals, Raises Price Target to $170